New treatment for viral arthritis reveals impressive results in Phase 2 human clinical trial

Griffith University’s Institute for Glycomics and Melbourne-based company Paradigm Biopharmaceuticals Limited (ASX: PAR) have reported impressive results from their Phase 2A clinical trials of a new drug candidate to treat viral arthritis (joint pain/stiffness) caused by mosquito-borne alphavirus infections, including the debilitating Ross River virus (RRV) and chikungunya virus (CHIKV).

Read the full article here

Related Articles